Storm Therapeutics, a Cambridge, England, UK-based drug discovery company tackling disease through modulating RNA modifying enzymes, raised an additional £14m bringing the total Series A financing to £30m.
The financing included funding from new investor, Seroba Life Sciences, with existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participating in the fundraise.
This extension will enable the company to advance its broad pipeline further in preclinical development and accelerate its programs towards the clinic.
Founded in 2015 by Dr Keith Blundy, CEO, Storm Therapeutics is a University of Cambridge spin-out translating the work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of drugs in oncology and other diseases. Storm is tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.
In addition, the company named Dr Mark Albertella as VP Translational Oncology.